Evidence map›Paper›PMID 36591297›Full record

ArticleFrontiers in immunology2022

Mucosa associated invariant T and natural killer cells in active and budesonide treated collagenous colitis patients.

Niki Daferera, Sofia Nyström, Henrik Hjortswang, Simone Ignatova, Maria C Jenmalm, Magnus Ström, Andreas Münch

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Niki DafereraDepartment of Gastroenterology, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Sofia NyströmDepartment of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Henrik HjortswangDepartment of Gastroenterology, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Simone IgnatovaDepartment of Pathology, Linköping University, Linköping, Sweden.
Maria C JenmalmDepartment of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Magnus StrömDepartment of Gastroenterology, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Andreas MünchDepartment of Gastroenterology, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Linköping University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Collagenous colitis (CC) is an inflammatory bowel disease, which usually responds to budesonide treatment. Our aim was to study the immunological background of the disease. Methods: Analyses of peripheral and mucosal MAIT (mucosa associated invariant T cells) and NK (natural killer) cells were performed with flow cytometry. Numbers of mucosal cells were calculated using immunohistochemistry. We studied the same patients with active untreated CC (au-CC) and again while in remission on budesonide treatment. Budesonide refractory patients and healthy controls were also included. The memory marker CD45R0 and activation marker CD154 and CD69 were used to further study the cells. Finally B cells, CD4 Results: The percentages of circulating CD56 Discussion: Patients with active collagenous colitis have lower percentages of circulating MAIT and NK cells. However, there was no change of these cells in the colonic mucosa. Most mucosal cell populations were increased in budesonide refractory as compared to au-CC patients, particularly the number of MAIT cells. This may indicate that T cell targeting therapy could be an alternative in budesonide refractory CC.

Indexed as

BudesonideColitis, CollagenousCD8-Positive T-LymphocytesHumansIntestinal MucosaKiller Cells, NaturalBudesonidebudesonidecollagenous colitisMAIT cellmicroscopic colitis (MC)natural killar cells

Identifiers

PMID36591297
PMCPMC9798420
OpenAlexW4311612555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.